Key result
Muscarinic acetylcholine receptor PET tracers currently lack broad clinical application, requiring further development to improve imaging properties for monitoring neurodegenerative diseases.
Why the study?
No muscarinic acetylcholine receptor PET tracer has found broad clinical application, demanding tracers with improved imaging properties to monitor disease progression and clarify receptor functions.
This review highlights the current state and challenges of developing clinically applicable PET tracers for muscarinic acetylcholine receptors to monitor neurodegenerative diseases.
This is the authors' abstract. We don't add key points for this paper.
The muscarinic cholinergic system regulates peripheral and central nervous system functions, and, thus, their potential as a therapeutic target for several neurodegenerative diseases is undoubted. A clinically applicable positron emission tomography (PET) tracer would facilitate the monitoring of disease progression, elucidate the role of muscarinic acetylcholine receptors (mAChR) in disease development and would aid to clarify the diverse natural functions of mAChR regulation throughout the nervous system, which still are largely unresolved. Still, no mAChR PET tracer has yet found broad clinical application, which demands mAChR tracers with improved imaging properties. This paper reviews strategies of mAChR PET tracer design and summarizes the binding properties and preclinical evaluation of recent mAChR tracer candidates. Furthermore, this work identifies the current major challenges in mAChR PET tracer development and provides a perspective on future developments in this area of research.
mAChR PET tracers may support neurodegenerative monitoring; leaves open prospective validation before clinical adoption.
No takes yet. Share an insight, caveat, or question.
Ozenil et al. (2021) conducted a review in Neurodegenerative diseases. Muscarinic acetylcholine receptor (mAChR) PET tracers was evaluated. Muscarinic acetylcholine receptor PET tracers currently lack broad clinical application, requiring further development to improve imaging properties for monitoring neurodegenerative diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Pharmaceuticals